Have you wanted to know about the future prediction of sun pharma for the upcoming year?
Today we will be talking about SunPharma which is a privately held pharmaceutical company (that makes medicines). The company’s full name is Sun Pharmaceuticals Industries Limited. The stock has risen sharply recently and has had a brilliant breakout, we also see major upside potential in this stock and are bullish over it. This is why we have decided to talk about the stock today.
In today’s post, we will be covering everything about SunPharma’s stock from what products this company makes. What are the technical charts saying for this company? After this, on the basis of technical analysis, we will talk about the future targets for this company. We will discuss all these aspects specifically how SunPharma has performed in the previous quarterly and annual results. Everything you need to know to invest in the stock is available here.
Friends, now let we are going to talk about the technical chart and technical aspects of the company. If you have a look at the chart for SunPharma in a week’s timeframe you will see that the stock has made a huge upside growth with a significantly large volume.
The stock broke resistance levels at 681 with volume and did go into a retracement but then accelerated after 550. We are very bullish on this stock. The stock has been also affected positively by the coronavirus pandemic after an initial decline and has been on a steady momentum with only minor retracements.
Product Analysis Of Sun Pharma
Before anything else, it is necessary to know about the company itself. The company makes products relating to medicines such as patented medicines, generic medicines, and everyday remedies like Volini and Revital. The company is led by Dilip Sanghvi who is also the Founder of the company (Source: SunPharma Product Page).
Sun Pharma Quarterly Result Analysis
According to ticker.finology.in, in the first quarter of 2021 (Q1FY21), the company sold Rs.3,665.29 crore, in which it lost Rs.138.28 crore after paying taxes. Similarly, in the second quarter of 2021 (Q2FY21), the company made a sale of Rs.4,143.15 crores, in which the company earned a profit of 809.07 crores after paying tax.
After this, in the third quarter of 2021 (Q3FY21), the company sold Rs.3,770.66 crores, in which the company made a profit of Rs.515.43 crores. After that, if seen, in the fourth quarter (Q4FY21) of 2021, the company sold 4,006.88 crores, of which the company made a loss of 1,286.21 crores.
After that, in the first quarter of 2022 (Q1FY22), the company performed better than before, selling 3,325.95 crores, in which the company got a profit of 419.30 crores after paying tax.
Sun Pharma Annual Result Analysis
Friends, if we talk about the company’s annual report, according to ticker.finology.in, the company sold 7,733.26 crores in 2016 (FY16), in which the company made a loss of 1,087.51 crores. In the next year March 2017 (FY17), the company did a business of 7,683.96 crores, in which the company earned a profit of -22.84 crores.
In the next year 2018 (FY18), the company did a business of 8,982.49 crores, in which the company earned a profit of 305.64 crores. After this, in the year 2019 (FY19), the company earned a profit of 816.60 crores, doing a business of 10,303.21 crores.
In FY20 (Year 2020), the company performed even better, doing business of 12,531.93 crores and profit of 3,211.14 crores to the company. The company made Rs.14,116.05 Cr. of sales and make a profit of Rs.842.40 Cr. in the FY21 and in the next year FY22 the company makes Rs.15,585.98 Cr. sales and makes Rs.99.99 Cr. of loss.
SunPharma Share Price Target 2022, 2023, 2024, 2025, And 2030: Friends, we have figured out possible target levels. These have been calculated using Fibonacci Retracement and we have calculated for you 7 targets that would be achieved year after year. This will you aid you to make better trading decisions.
Friends, the market is fast and changes quickly. Volumes are getting hired and people are getting more aware. After clearing this year stock investment growth is due to increase massively. Hence, the market will go up and up. So, for 2022 the first target is Rs.1065 and the second target is Rs.1105.
Friends, if the target for 2022 is met. The stock will rise due to the sentiment of the public rising in the stock and keeping the momentum up of the stock. And hence our prediction is Rs.1206 and the second prediction target is Rs.1448. The basic reason for this is the recovery of the economy will take time and would continue till 2023 as well.
Using Fibonacci Retracement even if a few times corrections do happen in the SunPharma stock it should go onto the levels of Rs.1567 and Rs.1744. This prediction can be attributed to the fact that the company management has been very reliable. This would be evident when we go over the Quarterly Analysis for SunPharma.
If you do hold the SunPharma stock till 2025 the predicted levels are Rs.2084 and Rs.2332. Long-term holding is recommended since it reduces risk, tax deductions, and also a hefty dividend (if you choose that option that is). Even without dividends the returns would pretty generous.
SunPharma would likely reach the levels of at least 2640, the second target for sun pharma share target 2030 is Rs.3019 and the third target for sun pharma 2030 is Rs.3551. This can be compounded by the fact that the company is 2nd in the Pharma sector in India in terms of size and as a long-term investor this would mean a very profitable return for the investment.
|Year||Target Of Sun Pharma|
|(Target-2)||Rs.3219 And Rs.3531|
So, in this post, we have seen what product SunPharma makes. The technical aspects cover the charts of its stock. We checked the quarterly and annual results. We talked in specific detail about everything you need to know in order to make the most informed decision before investing.
If you liked this post and got any benefit from it. Then do share it with your friends. For any questions ask us without hesitation and read more from the definitive source of financial analysis Dehati Trader.
I am a share market expert for the last five years. I have expertise in technical analysis, and fundamental analysis of stocks, and assets. On this website, I write content like analysis of shares, predict future targets of shares based on analysis, simplify technical analyses, and intraday trading.